LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

Home・Listă Acțiuni・Akebia Therapeutics Inc

Akebia Therapeutics Inc

Închisă

SectorSănătate

1.58 -1.86

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

1.55

Maxim

1.6099999999999999

Indicatori cheie
By Trading Economics
Venit	293K 540K
Vânzări	-3.7M 59M
Marjă de profit	0.919
Angajați	181
EBITDA	-1.2M 6.2M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+250% upside

Statistici piață
By TradingEconomics
Capitalizare de piață	-132M 430M
Deschiderea anterioară	3.44
Închiderea anterioară	1.58

Sentimentul știrilor

By Acuity

10%

90%

7 / 374 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bullish Evidence

2.345 / N/A Suport & Rezistență

Akebia Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

9 dec. 2025, 22:13 UTC

Câștiguri

GE Vernova Raises Outlook, Doubles Dividend on Energy Market Momentum

9 dec. 2025, 21:40 UTC

Câștiguri

GameStop Sales Fall as Collectibles Remain Only Bright Spot

9 dec. 2025, 18:51 UTC

Achiziții, Fuziuni, Preluări

Broadwood Partners Still Opposes Alcon's Higher Bid for Staar Surgical

9 dec. 2025, 16:57 UTC

Principalele dinamici ale pieței

Clear Secure Rises on Medicare Identity Verification Contract

9 dec. 2025, 23:46 UTC

Market Talk

Nikkei May Trade Rangebound Ahead of Fed Rate Decision -- Market Talk

9 dec. 2025, 23:46 UTC

Achiziții, Fuziuni, Preluări

Legend Holdings Stake in Lenovo Now at 32.34%

9 dec. 2025, 23:45 UTC

Achiziții, Fuziuni, Preluări

Legend Holdings: Remains Optimistic About Lenovo's Future Development Potential

9 dec. 2025, 23:44 UTC

Achiziții, Fuziuni, Preluări

Legend Holdings: Purchased Lenovo Shares at Average Price of HK$9.7653/Share

9 dec. 2025, 23:43 UTC

Achiziții, Fuziuni, Preluări

Legend Holdings: Acquired Lenovo Shares for Total Cash Consideration of HK$1.12B

9 dec. 2025, 23:43 UTC

Achiziții, Fuziuni, Preluări

Legend Holdings: Acquired 115.17M Lenovo Shares From Open Market Between Nov. 21 and Dec. 9

9 dec. 2025, 23:35 UTC

Market Talk

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

9 dec. 2025, 22:42 UTC

Câștiguri

PepsiCo Wants to Boost Sales, Cut Costs. The Street Is Doubtful. -- Barrons.com

9 dec. 2025, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

9 dec. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 dec. 2025, 21:48 UTC

Market Talk

Hiring Confidence Slips in Canada Entering 2026 -- Market Talk

9 dec. 2025, 21:36 UTC

Câștiguri

Casey's General Stores: Fiscal 2026 EBITDA Is Expected to Increase 15% to 17% >CASY

9 dec. 2025, 21:36 UTC

Câștiguri

Casey's General Stores: Total Inside Gross Profit Increased 13.5% to $703.4M Compared to Prior Yr >CASY

9 dec. 2025, 21:36 UTC

Câștiguri

Casey's General Stores: Now Expects Inside Same-Store Sales to Increase 3% to 4% and an Inside Margin of 41% to 42% >CASY

9 dec. 2025, 21:36 UTC

Câștiguri

Casey's General Stores: Same-Store Fuel Gallons Up 0.8% Compared to Prior Yr With Fuel Margin of 41.6 Cents per Gallon, Total Fuel Gross Profit Increased 20.9% to $377.4M Compared to Prior Yr >CASY

9 dec. 2025, 21:36 UTC

Câștiguri

Casey's General Stores: Inside Same-Store Sales Increased 3.3% Compared to Prior Yr, and 7.5% on 2-Yr Stack Basis, With an Inside Margin of 42.4% >CASY

9 dec. 2025, 20:28 UTC

Market Talk

Oil Futures Decline for Second Straight Session -- Market Talk

9 dec. 2025, 20:27 UTC

Achiziții, Fuziuni, Preluări

Teck Resources: Merger of Equals With Anglo Amer Plc Approved by Both Classes of Teck Hldrs

9 dec. 2025, 20:27 UTC

Achiziții, Fuziuni, Preluări

Teck Reports Voting Results From Special Meeting of Hldrs

9 dec. 2025, 20:26 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Moody's: Paramount's Warner Bid Makes Strategic Sense, With Risk -- Market Talk

9 dec. 2025, 20:21 UTC

Market Talk

U.S. Natural Gas Extends Pullback on Shifting Weather Outlook -- Market Talk

9 dec. 2025, 19:52 UTC

Câștiguri

Correction to 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com on Dec. 8

9 dec. 2025, 19:17 UTC

Câștiguri

Update: 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com

9 dec. 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 dec. 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

9 dec. 2025, 17:11 UTC

Câștiguri

Nvidia Has Permission to Sell H200 Chips to China. Why It Might Not Matter Much for the Stock. -- Barrons.com

Comparație

Modificare preț

Akebia Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

250% sus

Prognoză pe 12 luni

Medie 5.67 USD 250%

Maxim 6 USD

Minim 5 USD

În baza a 3 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruAkebia Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

3 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 3 analiști care au acordat evaluări ale acțiunilor Akebia Therapeutics Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

2.345 / N/ASuport & Rezistență

Recent bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

7 / 374 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Akebia Therapeutics Inc

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.